<DOC>
	<DOC>NCT00509210</DOC>
	<brief_summary>The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.</brief_summary>
	<brief_title>Study of Telaprevir in Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Clinically diagnosed with Child Pugh score of 79 or greater than 10 Women of nonchildbearing age Tested positive for HIV, Hepatitis C, Hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Liver Disease</keyword>
</DOC>